Skip to main content

Available studies

  • The following is a current list of our open, cancer-related research studies at Virginia Piper Cancer Institute locations, part of Allina Health. Patients can participate in the studies at the locations listed with each study.

    Breast cancer

    • Oncothyreon ONT-380-206 Her2+ Breast Cancer Study
      • Description: Study of ONT-380 vs placebo in combination with capecitabine + trastuzumab in metastatic HER2+ breast cancer - must have prior taxane, trastuzumab, pertuzumab and T-DM1
      • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus
    • Genentech/Roche WO40324 Her2 + Neoadjuvant Study
      • Description: Phase III study of SQ Fixed-dose pertuzumab and trastuzumab + Chemotherapy vs. IV Pertuzumab + IV Herceptin + Chemotherapy for Her2 + cancer with tumor size ≥ 2 cm or node-positive.
      • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus
    • Seattle Genetics SGN-LIV1A Study
      • Description: Safety study of SGN-LIV1A in patients with metastatic triple negative breast cancer as a single agent, and ER/PR neg/ Her2 positive metastatic breast cancer with trastuzumab
      • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus
    • Seattle Genetics SGN-LIV2 Study
      • Description: Phase 1b/2 Study of SGN-LIV1A + pembrolizumab for first-line treatment of  unresectable locally-advanced or metastatic triple negative breast cancer
      • Locations: Abbott Northwestern Hospital
    • MacroGenics CP-MGAH22-04 SOPHIA for HER2+ Metastatic Breast Cancer
      • Description: Phase 3 RCT of margetuzimab + chemotherapy vs. trastuzumab + chemotherapy for HER2+ Metastatic Breast Cancer
      • Location: Abbott Northwestern Hospital
    • Immunomedics IMMU-132-05 ASCENT Triple Negative Breast Cancer
      • Description: Phase 3 study of Sacituzumab Govitecan in relapsed/refractory triple-negative breast cancer for patients who have received at least two prior treatments
      • Location: Abbott Northwestern Hospital
    • Roche WO40181 ER+ Breast Cancer Study
      • Description: Phase II RCT of venetoclax + fulvestrant vs. fulvestrant in ER+, HER2 negative metastatic breast cancer after CDK4/6 inhibitor therapy
      • Location: Abbott Northwestern Hospital 
    • AVAILABLE FOR RURAL PATIENTS: Lally CaringGuidance Study
      • Description: Reducing distress and depressive symptoms in rural women after breast cancer diagnosis: Randomized Controlled Pilot Study
      • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus
      • Contact: Internet-based trial; contact Dr. Robin Lally at 402-559-5464.

    Colorectal cancer

    • NORDION TS-102 EPOCH Study
      • Description: A phase III clinical trial evaluating TheraSphere® in patients with metastatic colorectal carcinoma of the liver who have failed first line chemotherapy
      • Location: Abbott Northwestern Hospital
      • Description: Phase 2 study to evaluate TAK-931 single agent in patients with metastatic pancreatic cancer after 1st line therapy or metastatic CRC after ≥ 2 lines of therapy
      • Location: Abbott Northwestern Hospital


    • No available trials at this time

    Gastric cancer

    • No available trials at this time


    • No available trials at this time

    Gynecology cancers (cervical and ovarian cancer)

    • AZ LIGHT Ovarian Cancer Study
      • Description: Open-label Phase II study to assess olaparib tablets for patient with different HRD tumor status, platinum-sensitive, relapsed ovarian, fallopian tube or primary peritoneal cancer that have had at least 2 prior lines of chemotherapy
      • Location: TBD

    Head and neck cancer

    • No available trials at this time


    • No available trials at this time

    Hepatobiliary cancer

    • Mayo Hepatobiliary Registry and Biorepository
      • Description: International registry of hepatobiliary cancers including hepatocellular carcinoma, cholangiocarcinoma, and gallbladder adenocarcinoma, and unaffected individuals
      • Locations: Abbott Northwestern Hospital and Mercy Hospital – Mercy Campus

    Lung cancer

    • Dynavax DV9-NSC-01 Lung Cancer Study
      • Description: Phase 1b Dose Escalation and Expansion Trial of DV281 + Anti-PD-1inhibitor in advanced Non-Small Cell Lung Cancer.
      • Location: Abbott Northwestern Hospital


    • Debiopharm 1562-201 NHL Study
      • Description: Phase 2 study of Debio 1562+ rituximab in relapsed/refractory DLBC, FL, MZL/MALT or MCL Lymphoma
      • Locations: Abbott Northwestern Hospital & Mercy Hospital – Mercy Campus
    • Trovagene TROV-052 AML Study
      • Description: Phase 1b/2 study of PCM-075 + low-dose cytarabine or decitabine in Acute Myeloid Leukemia
      • Locations: Abbott Northwestern Hospital


    • BMS CA224-047 Melanoma
      • Description: Randomized, double blind study of relatlimab + nivolumab versus placebo + nivolumab in patients with previously untreated metastatic or unresctable melanoma
      • Location: Abbott Northwestern Hospital
    • Amgen 139 Talimogene Laherparepvec (T-VEC) Registry
      • Description: Registry study for patients who have previously received T-VEC
      • Location: Mercy Hospital – Mercy Campus

    Multiple myeloma

    • No available trials at this time

    Ovarian cancer

    Pancreatic cancer

      • HALOZYME HALO 109-301
        • Description: Phase 3 RCT of Gem/Abraxane + PEGylated recombinant Human Hyaluronidase (PEGPH20)/Placebo for HLA-high Stage IV previously untreated pancreas cancer
        • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus
      • ARMO AM0010-301 ARTIST 1 Pancreas Cancer Study
        • Description: Randomized phase 3 study of AM0010 + FOLFOX vs. FOLFOX alone as second-line therapy for metastatic pancreatic cancer that has progress after a first-line gemcitabine-containing regimen
        • Location: Abbott Northwestern Hospital
      • University of Minnesota Tissue Procurement Study
        • Description: Development of Oncolytic Adenovirus targeting cancer stem cells: Tissue procurement study from pancreatic or esophageal cancer surgery (Kamath/Kelsey 863-8716)
        • Location: Abbott Northwestern Hospital
      • Pancreatic Screening
        • Description: Registry Study to Determine the Utility and Feasibility of a Pancreatic Cancer Screening Program for Patients at High Risk of the Disease Based on Genetics and Family History (Rossi/Kelsey 863-8551)
        • Location: Abbott Northwestern Hospital

      Renal cell cancer

      • No available trials at this time

      Solid tumor

      • No available trials at this time

      Urothelial cancer

      • Astellas Urolothelial Cancer 7465-CL-0301
        • Description: Open-label, randomized phase 3 study of Enfortumab Vedotin vs. chemotherapy in previously treated locally advanced or metastatic urothelial cancer
        • Location: Abbott Northwestern Hospital
    • Contact us

      Call 612-863-8716.

      800 E. 28th St.
      Minneapolis, MN 55407

      Research program leaders